The Statistics core activities are performed by the Biostatistics Center of the ECOG-ACRIN Statistics and Data Management Center. The Biostatistics Center is responsible for design and analysis of all ECOG-ACRIN studies. The Biostatistics Center has two components, SDMC-DFCI at the Dana-Farber Cancer Institute, which has primary responsibility for therapeutic trials, and SDMC-Brown at Brown University, which has primary responsibility for diagnostic and imaging studies. The Center includes a group of highly experienced statisticians who are led by Drs. Constantine Gatsonis and Robert Gray. The Center also has expertise in computational biology and has access to leading experts in this field at DFCI and Brown. The research structure of ECOG-ACRIN is organized into a number of scientific committees, which are responsible for developing the Group's studies. ECOG-ACRIN statisticians are assigned to work with specific scientific committees. They participate fully in the development of scientific directions and collaborate on study concepts from the earliest discussions within the committees through the entire process of development. Statisticians are responsible for developing statistical designs and analysis plans to robustly address study's objectives. The Biostatistics Center is responsible for comprehensive monitoring of all EA studies, including producing reports for monitoring study progress and safety and producing confidential reports for the Data Safety Monitoring Committee, which include interim analyses of outcome when appropriate. Statisticians also produce comprehensive reports on study results at the completion of studies and collaborate with lead study investigators on the development of manuscripts. Statisticians also collaborate with investigators on design and analysis of the ECOG- ACRIN's translational science initiatives.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA180794-06
Application #
9627514
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-04-04
Budget End
2020-02-29
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Henderson, Tara O; Parsons, Susan K; Wroblewski, Kristen E et al. (2018) Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. Cancer 124:136-144
Dahlberg, Suzanne E; Gray, Robert J (2018) Pragmatic approaches to address expansion cohort design. Cancer 124:3290-3292
Rakovitch, E; Gray, R; Baehner, F L et al. (2018) Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. Breast Cancer Res Treat 169:359-369
Ristau, Benjamin T; Manola, Judi; Haas, Naomi B et al. (2018) Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial. J Urol 199:53-59
Wong, Yu-Ning; Manola, Judith; Hudes, Gary R et al. (2018) Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial. Clin Genitourin Cancer 16:e315-e322
Scott, David W; King, Rebecca L; Staiger, Annette M et al. (2018) High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood 131:2060-2064
Ailawadhi, Sikander; Jacobus, Susanna; Sexton, Rachael et al. (2018) Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8:67
Morgans, Alicia K; Chen, Yu-Hui; Sweeney, Christopher J et al. (2018) Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. J Clin Oncol 36:1088-1095
Tarhini, Ahmad A; Lee, Sandra J; Li, Xiaoxue et al. (2018) E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-?2b in Advanced Melanoma. Clin Cancer Res :
Lubner, Sam; Feng, Yang; Mulcahy, Mary et al. (2018) E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist 23:1006-e104

Showing the most recent 10 out of 187 publications